Ipsen confirms U.S. FDA accepts new drug application for palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva

Ipsen

28 May 2021 - New drug application granted priority review status, with a decision anticipated on 30 November 2021.

Ipsen today announced that its new drug application for palovarotene, an oral, investigational, selective RARγ agonist for the prevention of heterotopic ossification as a potential treatment option for people living with the progressive disabling and ultra-rare genetic disorder fibrodysplasia ossificans progressiva, has been accepted by the U.S. FDA.

Read Ipsen press release

Michael Wonder

Posted by:

Michael Wonder